Please login to the form below
50
Revenue 2017Levemir
The Top Pharma List's top 50 pharmaceutical products by global sales ranking is compiled from GlobalData's pharmaceutical revenue figures. Levemir was produced by Novo Nordisk.
Sanofi to cut US insulin prices by up to 78% in January 2024
Novo Nordisk made a similar series of cuts last week, announcing a 75% reduction to the list price of its NovoLog insulin and a 65% reduction for Novolin and Levemir.
Novo Nordisk suspended from ABPI over ‘serious’ code of practice breaches
price of the company’s NovoLog insulin and a 65% reduction for Novolin and Levemir.
Novo Nordisk to cut US insulin prices by up to 75% in January 2024
The changes will come into effect in January 2024 and include a 75% reduction to the list price of its NovoLog insulin and a 65% reduction for Novolin and Levemir.
New drugs drive Novo Nordisk despite insulin price pressures
scrutinised. Sales in Novo's insulin franchise have flat-lined as sales of its newer products were off-set by pricing pressure on its older products, such as Levemir (insulin detemir).
Novo bolstered by new diabetes, obesity products
Sales of long-acting insulin also decreased by 2%, which was driven by declining Levemir sales.
Data provided by GlobalData
GlobalData is the premier source of research and consulting solutions for the pharmaceutical and medical device industries. With the combined expertise of more than 600 researchers, market analysts and consultants, we deliver high-quality, accurate and transparent industry insight that helps our clients to achieve growth and increase business value.
To find out more about how our research and consulting solutions can help you, please visit healthcare.globaldata.com
For more details on the data and methodology used to create the Top Pharma Lists, please visit PMLiVE's Top Pharma List - Methodology
Subscribe to our email news alerts
- Senior Medical Copywriter - Highly Awarded Advertising Agency
- £50,000 - £60,000 yearly
- Account Manager, Healthcare Marketing Creative Agency, Fixed ter...
- Highly competitive salary
- Account Manager, 6 month contract, Healthcare Brand communicatio...
- Highly competitive salary
- Home Based Account Manager, Medical Communications, UK, Pharma/M...
- Highly competitive salary
- Account Director, Healthcare Marketing Creative Agency, Fixed te...
- Highly competitive salary
- Market Access Director, six figure base salary and £5K joining b...
- Highly competitive salary
- BMS and Janssen’s antithrombotic granted FDA fast track designation
- Sanofi's frexalimab shows promise in relapsing forms of MS
- COVID-19: Pfizer’s Paxlovid approved by FDA and Gilead’s Veklury recommended by CHMP
- Decision date for Sarepta’s Duchenne muscular dystrophy gene therapy delayed by FDA
- Seqera Labs and Genomics England partner to progress genomic research
- AbbVie’s Rinvoq receives FDA approval for Crohn’s disease
- Pfizer’s antibiotic combination shows promise in treating multi-drug resistant infections
- Supporting the most vulnerable: why pharma should get behind the NHS’ healthcare equity campaign
- Healing the Healers
- The (inevitable) digital transformation of Medical Affairs
- Novartis receives EC approval for Cosentyx in hidradenitis suppurativa
- Pfizer’s RSV vaccine approved by FDA for older adults
No results were found
PMHub
OPEN Health
OPEN Health brings together deep scientific knowledge, global understanding, and broad specialist expertise to support our clients in improving health...
Latest intelligence
- Healing the Healers
- Because if we do not heal the healers, who is going to heal us?...
- The (inevitable) digital transformation of Medical Affairs
- It’s not a question of ‘if,’ it’s a question of ‘when.’...
- Oncology eBook: Reducing the care gap in cancer prevention, diagnosis, and treatment
- Despite significant innovation in the oncology landscape, there is a growing care gap preventing patients accessing and benefiting from innovations in cancer treatment. In this new publication, our oncology experts...
